2. Search Result
Search Result
Results for "

NIK kinase

" in MedChemExpress (MCE) Product Catalog:

12

Inhibitors & Agonists

1

Fluorescent Dyes

3

Recombinant Proteins

4

Antibodies

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-112433
    NIK SMI1
    15+ Cited Publications

    		 NF-κB Inflammation/Immunology
    NIK SMI1 is a potent, selective NF-κB inducing kinase (NIK) inhibitor, which inhibits NIK-catalyzed hydrolysis of ATP to ADP with IC50 of 0.23±0.17 nM. NIK SMI1 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.
    NIK SMI1
  • HY-120501
    B022
    Maximum Cited Publications
    17 Publications Verification

    		 NF-κB Inflammation/Immunology
    B022 is a potent and selective NF-κB-inducing kinase (NIK) inhibitor (Ki of 4.2 nM; IC50=15.1 nM). B022 protects liver from toxin-induced inflammation, oxidative stress, and injury . B022 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.
    B022
  • HY-145801
    XT2
    2 Publications Verification

    		 NF-κB Inflammation/Immunology
    XT2 is a potent, orally active, and selective inhibitor of NF-κB-inducing kinase (NIK) with an IC50 of 9.1 nM. XT2 suppresses CCl4-induced upregulation of ALT, a key biomarker of acute liver injury. XT2 also decreases immune cell infiltration into the injured liver tissue. XT2 has the potential for the research of liver inflammatory diseases . XT2 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.
    XT2
  • HY-153516
    NIK-IN-2

    		NF-κB Cancer
    NIK-IN-2 (compound 1) is a potent inhibitor of NF-κB-inducing kinase (NIK), with the pIC50 of 7.4. NIK-IN-2 plays an important role in cancer research .
    NIK-IN-2
  • HY-112433A
    (S)-NIK SMI1

    		NF-κB Drug Isomer Inflammation/Immunology
    (S)-NIK SMI1 is the isomer of NIK SMI1 (HY-112433), and can be used as an experimental control. NIK SMI1 is a potent, selective NF-κB inducing kinase (NIK) inhibitor, which inhibits NIK-catalyzed hydrolysis of ATP to ADP with IC50 of 0.23±0.17 nM.
    (S)-NIK SMI1
  • HY-172545
    AMG28

    		Tau Protein Neurological Disease
    AMG28 is an ATP-competitive inhibitor targeting TTBK1 and TTBK2, with IC50 values of 805 nM and 988 nM, respectively. AMG28 inhibits the phosphorylation of tau protein at the Ser422 site .
    AMG28
  • HY-176061
    NIK ligand 1

    		NF-κB Cancer
    NIK ligand 1 (compound 2) is a NF-κB inducing kinase (NIK) ligand .
    NIK ligand 1
  • HY-149696
    IR-Crizotinib

    		NF-κB Cancer
    IR-Crizotinib is a NF-κB-inducing kinase (NIK) inhibitor that crosses the blood-brain barrier and fluorescently localizes intracranial glioblastoma (GBM) in mice (IC50=3.381 μM). IR-Crizotinib is conjugated from the near-infrared dye IR-786 and the NF-κB-inducing kinase (NIK) inhibitor Crizotinib. IR-Crizotinib can effectively inhibit the growth and invasion of glioma in vitro and in vivo and can be used in cancer research .
    IR-Crizotinib
  • HY-149043
    NIK-IN-1

    		NF-κB Metabolic Disease
    NIK-IN-1 (Compound 2) is an inhibitor of NF-κB-inducing kinase (NIK). NIK-IN-1 is used for research on hepatic inflammatory diseases and acute liver injury .
    NIK-IN-1
  • HY-124865
    MAP3K14-IN-1

    		MAP3K IKK Cancer
    MAP3K14-IN-1 (Compound 173) is a MAP3K14 (NIK kinase) inhibitor with an IC50 of 1.8 nM. MAP3K14-IN-1 inhibits the autophosphorylation of MAP3K14 kinase. MAP3K14-IN-1 reduces the level of phosphorylated IKKα in cancer cells. MAP3K14-IN-1 inhibits the proliferation of multiple myeloma cells. MAP3K14-IN-1 can be used in research related to multiple myeloma .
    MAP3K14-IN-1
  • HY-179701
    NIK-IN-3

    		NF-κB TNF Receptor Interleukin Related CXCR Inflammation/Immunology
    NIK-IN-3 is a potent and orally active NF-κB-inducing kinase (NIK) inhibitor with an IC50 of 5.2 nM. NIK-IN-3 suppresses non-canonical NF-κB pathway activation and inhibits the secretion of pro-inflammatory cytokines, such as TNF-α, IL-6, IL-1β and chemokine CXCL12. NIK-IN-3 shows significant anti-inflammatory effects in LPS (HY-D1056)-induced sepsis mice model and DSS (HY-116282)-induced colitis model. NIK-IN-3 can be used for the research of inflammation, such as colitis .
    NIK-IN-3
  • HY-117222
    AM-0216

    		NF-κB Inflammation/Immunology Cancer
    AM-0216 is a highly selective NF-κB-inducing kinase (NIK) inhibitor with a Ki value of 2 nM. AM-0216 is promising for research of NF-κB-dependent hematologic malignancies (e.g., multiple myeloma) and autoimmune diseases .
    AM-0216

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: